Hepalink adding biologics CDMO Cytovance in $200m acquisition
API supplier Hepalink will buy Cytovance for $206m (€183m) in a deal the biologics CDMO says will help expedite its expansion plans.
Archives for August 27, 2015
Immatics GmbH founds $60m US T-cell spin-out
German biotech Immatics and the University of Texas have spent $60m on spin-out Immatics US to specialise in adoptive cellular therapies (ACT) for cancer.
FDA opts for four-letter suffix to distinguish biologics and biosimilars
The US FDA has published long-awaited guidelines on the non-proprietary naming of biological products, but biosimilar makers say adding a random four-letter suffix could needlessly complicate the prescribing system.
Shire to use new suppliers to up production of HAE drug filtered from US plasma
Shire will use contractors to increase production of Cinryze, the half billion dollar-a-year Hereditary Angioedema (HAE) drug it bought with ViroPharma in 2014.